<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421627</url>
  </required_header>
  <id_info>
    <org_study_id>ZYS2015-01</org_study_id>
    <nct_id>NCT02421627</nct_id>
  </id_info>
  <brief_title>Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
  <official_title>Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute of Acupuncture, Moxibustion and Meridian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute of Acupuncture, Moxibustion and Meridian</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the safety and efficacy of moxibustion on diarrhea-predominant irritable bowel
      syndrome and evaluation by Magnetic Resonance Imaging (MRI), Event related potential (ERP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. A randomized controlled trial

        2. Moxibustion treatment, sham control

        3. To observe the safety and efficacy of moxibustion treatment versus placebo control

        4. Evaluation by intestinal microbial structural and diversity changes using 16S rDNA
           sequencing

        5. Evaluation by structural MRI and resting state-functional MRI

        6. Evaluation by ERP
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total efficacy (Adequate relief responder)</measure>
    <time_frame>Week 6</time_frame>
    <description>The ratio of the number of responders and the total number of participants in each group. Adequate relief responder is the participant who considered effective treatment in the self-assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total efficacy (Adequate relief responder)</measure>
    <time_frame>Week 12, 18 and 24</time_frame>
    <description>Differences in Adequate relief responder between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity score (SSS)</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>Differences in the mean changes of SSS score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of responder to SSS</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>The differences of the proportion of responders between groups. Defined the SSS score decreased more than 50 points from baseline as responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol stool form scale (BSS)</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>Differences in the mean changes of BSS score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (IBS-QOL)</measure>
    <time_frame>Week 6</time_frame>
    <description>Differences in the mean changes of IBS-QOL score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital anxiety and depression score (HADS)</measure>
    <time_frame>Week 6</time_frame>
    <description>Differences in the mean changes of HADS score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating anxiety scale (SAS)</measure>
    <time_frame>Week 6</time_frame>
    <description>Differences in the mean changes of SAS score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating Depression Scale (SDS)</measure>
    <time_frame>Week 6</time_frame>
    <description>Differences in the mean changes of SDS score from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea frequency per day</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>Differences in the mean changes of Diarrhea frequency per day from baseline between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency of defecation</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>Differences in the mean changes of Urgency of defecation from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation (Number of participants with treatment-related adverse events as assessed by CTCAE v4.0)</measure>
    <time_frame>Week 6, 12, 18 and 24</time_frame>
    <description>Eg.moxibustion related burns, blistering, etc</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Brain structures （gray matter, white matter）MRI</measure>
    <time_frame>Week 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>resting-state functional MRI</measure>
    <time_frame>Week 6</time_frame>
    <description>Analysis with methods of regional homogeneity，ALFF/fALFF，functional connectivity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnetic Resonance Spectroscopy (MRS)</measure>
    <time_frame>Week 6</time_frame>
    <description>The ratio of glutamate complex (Glx) peak area and creatine ratio (Cr) of the cingulate cortex and insula.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event-related potentials (ERP)</measure>
    <time_frame>Week 6</time_frame>
    <description>Measurement of brain resting state energy atlas and the amplitude changes of each major components during the task and latency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intestinal microbiota changes</measure>
    <time_frame>Week 6</time_frame>
    <description>Fecal microbial structural and diversity changes</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain-gut microbiota interaction</measure>
    <time_frame>Week 6</time_frame>
    <description>Multiple regression analysis to establish the association between intestinal microbiota and brain</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Moxibustion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving moxibustion treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham moxibustion group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Receiving sham moxibustion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>moxibustion</intervention_name>
    <description>Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.</description>
    <arm_group_label>Moxibustion group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham moxibustion</intervention_name>
    <description>Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.</description>
    <arm_group_label>Sham moxibustion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diarrhea-predominant IBS patients who met the Rome III diagnostic criteria;

          2. Age 18-65 years old, male or female;

          3. Volunteered for the trial, signed the informed consent

        Exclusion Criteria:

          1. Intestinal organic disease;

          2. Constipation-predominant IBS;

          3. Alternating diarrhea and constipation IBS;

          4. Unstructured IBS;

          5. At the same time, application of smecta, dicetel, cisapride or traditional Chinese
             medicine;

          6. Combined liver, kidney, heart or mental disease patients;

          7. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huangan Wu, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai University of TCM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Institute of Acupuncture, Moxibustion and Meridian</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200082</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yueyang Integrated Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200437</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moxibustion</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

